Holen Sie sich die Stockscreener-App
112.68
1.09%
1.21
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$111.47
Offen:
$111.77
24-Stunden-Volumen:
7.69M
Relative Volume:
0.89
Marktkapitalisierung:
$195.94B
Einnahmen:
$44.33B
Nettoeinkommen (Verlust:
$6.48B
KGV:
30.43
EPS:
3.7033
Netto-Cashflow:
$6.92B
1W Leistung:
+1.67%
1M Leistung:
-9.35%
6M Leistung:
-12.92%
1J Leistung:
-14.50%
1-Tages-Spanne:
$111.40
$113.11
1-Wochen-Bereich:
$109.50
$113.76
52-Wochen-Spanne:
$105.27
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio - GuruFocus
EXACT SCIENCES CORP SEC 10-K Report - TradingView
ABT.SW Abbott Laboratories (SIX) volume spike 40x avg: watch CHF100.00 support - Meyka
Abbott Laboratories $ABT Shares Purchased by Public Sector Pension Investment Board - MarketBeat
Krilogy Financial LLC Acquires Shares of 9,560 Abbott Laboratories $ABT - MarketBeat
Freemont Management S.A. Trims Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next? - 24/7 Wall St.
DexCom earnings up next: Can G7 rollout offset Abbott competition? By Investing.com - Investing.com Nigeria
DexCom earnings up next: Can G7 rollout offset Abbott competition? - Investing.com
Abbott Labs: The healthcare dividend stock I'd happily hold forever - MSN
Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever - AOL.com
Illinois Municipal Retirement Fund Has $22.46 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Cibc World Market Inc. Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Caisse Des Depots ET Consignations Buys 9,374 Shares of Abbott Laboratories $ABT - MarketBeat
‘Time to Buy,’ Says Options Trader Following Abbott’s (ABT) Earnings Implosion - TipRanks
Rhumbline Advisers Sells 57,100 Shares of Abbott Laboratories $ABT - MarketBeat
Jensen Investment Management Inc. Has $322.72 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Drug of Abuse Testing Market Is Going to Boom |• Abbott - openPR.com
ING Groep NV Has $63.40 Million Holdings in Abbott Laboratories $ABT - MarketBeat
US Says Abbott Lied, Must Repay Funds Spent On Formula - Law360
Exact Sciences Faces Shareholder Lawsuits Over Abbott Merger - TipRanks
Abbott stock rises on AFib device data buzz as traders weigh FDA overhang - Bez Kabli
Abbott Laboratories price tries to correct main downward trendForecast today10-02-2026 - Economies.com
After a 15% Drop, Is Abbott Stock Set Up for a Comeback in 2026? - TIKR.com
Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica - GlobeNewswire Inc.
Wealthfront Advisers LLC Reduces Stock Position in Abbott Laboratories $ABT - MarketBeat
Johnson Investment Counsel Inc. Has $130.71 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
S&CO Inc. Sells 16,992 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Rockland Trust Co. - MarketBeat
Abbott details Volt, TactiFlex data; Pulse Biosciences’ results shine - MedTech Dive
Candriam S.C.A. Boosts Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by ProShare Advisors LLC - MarketBeat
Assessing Abbott Laboratories (ABT) Valuation After New AFib Catheter And Pulsed Field Ablation Data - simplywall.st
Diamond Hill Capital Management Inc. Sells 309,225 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating - Finviz
Alps Advisors Inc. Acquires 82,455 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy - TechStock²
Analysts’ Top Healthcare Picks: Mettler-Toledo (MTD), Abbott Laboratories (ABT) - The Globe and Mail
Insider Stock Buying Reaches US$3.10m On Abbott Laboratories - Yahoo Finance
Canada Post Corp Registered Pension Plan Purchases 94,730 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Lessened by Twin Capital Management Inc. - MarketBeat
Top Abbott Insider Quietly Makes a Bold Million-Dollar Move - TipRanks
Abbott Labs CEO makes $2M bet as stock sinks - thestreet.com
Abbott Laboratories Announces Measurable Results From LATAM Diagnostic Market Development and Training Initiative Led by Claudia Marcela Riaño Caro - PRWeb
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
Abbott Laboratories (NYSE:ABT) Director Daniel Starks Purchases 10,000 Shares - MarketBeat
William Blair Maintains Abbott Laboratories(ABT.US) With Buy Rating - 富途牛牛
Abbott studies support pulsed field ablation, dual ablation catheters - MassDevice
Abbott Stock: 2026 Recovery Outlook After a 17% Decline - TIKR.com
Abbott (ABT) Showcases Promising AFib Therapy Advances at Boston Symposium - GuruFocus
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):